HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

RS-1269

structure in first source

Also Known As:

3-(isobutyrylamino)-N-(2-((2R)-2-phenyl-4-(4-pyridin-4-ylbenzyl)morpholin-2-yl)ethyl)benzamide

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Etori, Maki: 1 article (10/2010)
2.	Jojima, Takaaki: 1 article (10/2010)
3.	Kawashima, Kayo: 1 article (10/2010)
4.	Kuribayashi, Takeshi: 1 article (10/2010)
5.	Nakagami, Yasuhiro: 1 article (10/2010)
6.	Nara, Futoshi: 1 article (10/2010)
7.	Suzuki, Chie: 1 article (10/2010)
8.	Yamashita, Makoto: 1 article (10/2010)
9.	Yonekubo, Kazuki: 1 article (10/2010)

Related Diseases

1.	Shock 10/01/2010 - "We then investigated the pharmacological effects of RS-1269 on ovalbumin-induced ear swelling and lipopolysaccharide-induced endotoxic shock in mice. " 10/01/2010 - "A novel CC chemokine receptor 4 antagonist RS-1269 inhibits ovalbumin-induced ear swelling and lipopolysaccharide-induced endotoxic shock in mice."
2.	Necrosis 10/01/2010 - "The ear thickness was significantly decreased by oral administration of RS-1269 at the dose of 30 mg/kg. Treatment with lipopolysaccharide significantly increased the serum level of tumour necrosis factor-α. "
3.	Atopic Dermatitis (Atopic Eczema) 10/01/2010 - "Compared with an anti-CCL17 antibody, RS-1269 significantly inhibited the production at the dose of 100 mg/kg. These results raise the possibility that RS-1269 or one of its derivatives has potential to serve as a prototype compound to develop therapeutic agents for atopic dermatitis and inflammatory diseases."

Related Drugs and Biologics

1.	CCR4 Receptors
2.	Ovalbumin
3.	Lipopolysaccharides

Related Therapies and Procedures

1.	Oral Administration